Quratis Inc is a Korea-based company primarily engaged in the manufacture and sale of biopharmaceuticals. The Company is engaged in the manufacture and sale of vaccine, peptide nucleic acid complex. The Company is also engaged in the provision of Cell Penetrating Peptide (CPP) platform services. In addition, the Company is engaged in the development and research of vaccines, such as tuberculosis vaccines for adults and adolescents, and COVID-19 vaccines.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-03	₩2,745.00	+2.43%	19,353
26-09-03	₩2,680.00	-3.42%	36,048
26-09-02	₩2,775.00	-0.72%	14,929
26-09-01	₩2,795.00	+1.64%	14,512
26-08-31	₩2,750.00	+0.92%	19,011

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-09-04			5-day change	1st Jan Change
2,745.00 ^KRW	+2.43%		0.00%	-76.54%

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI

Market Cap	32.2B 23.91M 20.57M 19.35M 17.68M 33.08M 2.26B 33.17M 229M 88.75M 1.16B 89.77M 87.81M 3.73B	P/E 2024	-9.06x	P/E 2025	-28.4x
Enterprise Value	32.34B 24.02M 20.67M 19.44M 17.76M 33.23M 2.27B 33.32M 230M 89.16M 1.16B 90.19M 88.22M 3.75B	EV / Sales 2024	136x	EV / Sales 2025	43.3x
Free-Float	37.62%	Yield 2024 *	-	Yield 2025	-

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
02-25	Inventage Lab, Inc. agreed to acquire an additional 12.79% stake in Quratis Inc. for KRW 13.5 billion.	CI
12-23	Quratis wins contract amount of 1 billion won	RE
25-08-21	Access to Advanced Health Institute Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines	CI
25-06-19	Quratis To Invest 7 Billion Won In New Facility	RE
25-03-11	Quratis Inc. announced that it has received KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
25-02-20	Quratis Inc. announced that it has received KRW 15 billion in funding from Inventage Lab, Inc.	CI
24-11-24	Quratis Inc. announced that it expects to receive KRW 6.4993 billion in funding from Inventage Lab, Inc.	CI
24-11-14	Quratis Inc. announced that it has received KRW 10.4648 billion in funding from LINFRA Corp	CI
24-09-11	Quratis Inc. announced that it expects to receive KRW 10.4648 billion in funding from LINFRA Corp	CI
23-11-29	Quratis Inc. announced that it has received KRW 7.99999791 billion in funding from LINFRA Corp	CI
23-09-24	Quratis Inc. announced that it expects to receive KRW 7.99999791 billion in funding	CI

1 day	+2.43%
Current month	-0.18%
1 month	+24.49%
3 months	-40.43%
6 months	-72.15%
Current year	-76.54%

Quratis Inc. Stock

Stocks

A348080

KR7348080003

Pharmaceuticals

Valuation : Quratis Inc.

Chart: Quratis Inc.

Latest news : Quratis Inc.

Press Releases : Quratis Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Quratis Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	2,605	2,990
1 month	2,365	5,010
Current year	1,765	13,050
1 year	1,765	13,365
3 years	1,765	36,270
5 years	1,765	60,210
10 years	1,765	60,210

Manager	Title	Age	Since
Seong Kim CEO	Chief Executive Officer	52	2024-12-15
Chi-Yeol Kim AUD	Comptroller/Controller/Auditor	48	2025-04-06

Director	Title	Age	Since
Dong-Hun Kim CHM	Chairman	56	2025-02-19
Hyeong-Gi Choi BRD	Director/Board Member	39	2025-02-19
Taek-Dong Kim BRD	Director/Board Member	63	2025-02-19

Date	Insider	Type	Quantity	% Market Cap.
5/7/25	Ki-Young Yang	Others	80,000	0.1380%
5/9/24	Woo Ryu Sung	Others	41,946	0.0995%
4/2/24	Sang-Rae Cho	Others	118,333	0.2807%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
QURATIS INC.	+2.43%	0.00%	-70.01%	-89.90%	23.15M
ELI LILLY AND COMPANY	-1.17%	-2.40%	+54.31%	+105.37%	1,034B
JOHNSON & JOHNSON	-0.65%	+3.10%	+54.59%	+71.98%	671B
ABBVIE INC.	-1.22%	+0.68%	+20.77%	+76.06%	460B
ROCHE HOLDING AG	+0.14%	-0.47%	+29.49%	+38.56%	353B
NOVARTIS AG	-1.33%	+4.72%	+24.69%	+45.55%	309B
ASTRAZENECA PLC	-1.15%	+0.30%	-1.49%	+12.31%	255B
AMGEN INC.	-1.37%	+1.25%	+56.32%	+72.37%	240B
NOVO NORDISK A/S	-0.88%	+1.15%	-17.09%	-54.39%	207B
GILEAD SCIENCES, INC.	-0.15%	+3.67%	+33.93%	+100.94%	188B
Average	-0.52%	+1.13%	+18.55%	+37.89%	371.68B
Weighted average by Cap.	-0.91%	+1.04%	+36.67%	+66.74%

	2024	2025
Net sales	374M 278K 239K 225K 205K 384K 26.21M 385K 2.66M 1.03M 13.45M 1.04M 1.02M 43.31M	2.46B 1.82M 1.57M 1.48M 1.35M 2.52M 172M 2.53M 17.45M 6.77M 88.38M 6.85M 6.7M 285M
Net income	-26.27B -19.5M -16.78M -15.79M -14.42M -26.98M -1.84B -27.06M -187M -72.41M -945M -73.24M -71.64M -3.04B	-29.67B -22.03M -18.96M -17.84M -16.3M -30.48M -2.08B -30.57M -211M -81.8M -1.07B -82.74M -80.93M -3.44B
Net Debt	16.3B 12.1M 10.41M 9.8M 8.95M 16.74M 1.14B 16.79M 116M 44.93M 586M 45.45M 44.45M 1.89B	149M 111K 95.26K 89.63K 81.88K 153K 10.45M 154K 1.06M 411K 5.36M 416K 407K 17.28M